Contains Nonbinding Recommendations

Draft Guidance on Stiripentol

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Stiripentol

Dosage Form; Route: Capsule; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 500 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional comments: None

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 500 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional comments: None

Analyte to measure (in appropriate biological fluid): Stiripentol in plasma

Bioequivalence based on (90% CI): Stiripentol

Waiver request of in vivo testing: 250 mg based on (i) acceptable bioequivalence studies on the 500 mg strength, (ii) acceptable in-vitro dissolution testing of both strengths, and (iii) proportional similarity of the formulations across both strengths

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units for each strength of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.

Recommended Mar 2020